Cytokine-induced antiapoptotic molecule (CIAPIN1), a newly identified apoptosis inhibitor, has been found to participate in the process of proliferation and tumorigenicity for several cancers. The aim of this study was to evaluate the prognostic value of CIAPIN1 in pancreatic cancer and to probe its function in pancreatic carcinogenesis. We found that CIAPIN1 protein was absent or reduced in pancreatic cancer cell lines. There was also a loss or decrease in CIAPIN1 expression in 118 cases of pancreatic cancer tissues as compared with that in 82 cases of normal pancreatic tissues. In a Cox proportional hazards model, CIAPIN1 expression independently predicted better survival (Po0.0001). Adenoviral-mediated restoration of CIAPIN1 expression greatly repressed the proliferation of pancreatic cancer cell in vitro and suppressed the tumorigenicity of pancreatic cancer cell in Balb/ c nude mice. Our data also revealed that inhibition of pancreatic cancer cells proliferation by enforcing CIAPIN1 expression at least partly through delaying cell cycle progression and inducing cell apoptosis. In summary, our work revealed a novel function of CIAPIN1, which might possibly be used as an independent prognostic factor and a potential therapeutic target for pancreatic cancer.
INTRODUCTION
Pancreatic cancer is highly lethal, with median survival time of o6 months and an overall 5-year survival rate of all patients is o1%. 1 It is the fourth leading cause of cancer-related deaths in the United States. 2 According to the American Cancer Society, there are an estimated 42 470 new cases and 35 240 deaths from pancreatic cancer in the United States in 2009. 3 The lethal nature of pancreatic cancer is due to late detection, fast growth, a feature to invade and metastasize, and resistance to traditional therapy. It is a critical need for finding a new molecularly targeted therapy that can improve the outcome for those diagnosed with pancreatic cancer.
CIAPIN1 (cytokine-induced antiapoptosis inhibitor 1) is a newly identified apoptosis inhibitor with no homology to apoptosis regulatory molecules of the Bcl-2 family, caspase family or signal transduction molecules, is proven to be a mediator of the RAS signaling pathway and has an important role in fetal liver hematopoiesis. 4 Additionally, CIAPIN1 protects Ba/F3 cells against etoposide, gamma radiation and stauroporine in vitro. 4 In addition, our previous study confirmed that CIAPIN1 was upregulated in several multidrug resistance cancer cell lines and might have a role in mediating multidrug resistance of cancer cells. 5, 6 Furthermore, CIAPIN1 expression was correlated with malignant phenotype of several cancers such as gastric cancer, liver cancer, esophagus cancer, lung cancer, lymphoma and kidney cancer, 7--15 which strongly suggested that CIAPIN1 might be an important protein involving in tumorigenicity and carcinogenesis.
Although the expression level of CIAPIN1 has been found to relate to many different solid tumors and may act as an oncogene or tumor suppressor in different tumor types, the role of CIAPIN1 in pancreatic cancer is still unknown. To further elucidate the biological role of CIAPIN1, in the present study, we examined the expression of CIAPIN1 in tumor tissue specimens obtained from patients with resected pancreatic cancer and its effect on the patients' survival duration. We found that loss of CIAPIN1 expression directly correlated with decreased survival. We also found that restoration of CIAPIN1 expression inhibited the growth and proliferation of human pancreatic cancer cells in vitro and in vivo. Induction of cell cycle arrest and apoptosis was at least in part responsible for the antitumor activity of CIAPIN1. In conclusion, our experiment results indicated that CIAPIN1 was a significant prognostic factor, and targeting of CIAPIN1 was a potential treatment modality for human pancreatic cancer.
MATERIALS AND METHODS

Ethics statement
This study was performed in accordance with the principles embodied in the Declaration of Helsinki. All experimental procedures were approved by No neo-adjuvant radio-or chemotherapy was applied before surgical resection to any patient. Table 1 showed the details of the patients' characteristics and CIAPIN1 expression situation. Histologic grading and staging of all tumors were performed according to the TNM classification system of the International Union against Cancer. 16 
Immunohistochemistry
Sections were cut at 4-mm thickness from paraffin-embedded material, deparaffinized in xylene and rehydrated through a graded ethanol series. Endogenous peroxidase activity was blocked by incubating with 3% hydrogen peroxide in methanol for 30 min. Antigen retrieval was achieved by microwaving the sections in citrate buffer at pH 6.0. Each section was exposed to 10% nonimmunized rabbit serum for 10 min to block nonspecific binding of the antibodies, followed by incubation with a mouse anti-CIAPIN1 monoclonal antibody (produced in our laboratory 1 : 300 dilution) at 4 1C overnight. The sections were then sequentially incubated with a biotinylated anti-mouse immunoglobulin solution for 20 min followed by peroxidase-labeled streptavidin for 20 min. The reaction products were visualized using 3,3-diaminobenzidine as a chromogen followed by nuclear counterstaining with hematoxylin.
Two independent investigators scored the sections without any knowledge of the clinical features of each case. An average value of two independent scores was presented in the present study. Depending on the percentage of positive cells and staining intensity, CIAPIN1 staining positivity was classified into three groups: negative, weak positive and strong positive, as described previously. 17 Cell culture and adenovirus infection Human pancreatic cancer cell lines PANC-1, BxPC-3, ASPC-1 (purchased from American Type Culture Collection, Manassas, VA, USA), PC-2 and PC-3 (established in Peking Union Medical College) 18 were maintained in our laboratory and cultivated in RPMI 1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10% heat-inactivated FCS, penicillin (100 units ml --1 ), and streptomycin (100 Ag ml --1 ) in a CO2 incubator (Forma Scientific, Waltham, MA, USA). Preparation and construction of Ad-CIAPIN1 and Ad-EGFP vector, and adenovirus titration were carried out as previously described Chen et al. 18 PC-2 and PANC-1 pancreatic cancerderived cell lines were transduced using standard techniques as previously reported. 19 Cell proliferation assay
The proliferation of cells was evaluated as previously described. 20 By the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical, St Louis, MO) into water-insoluble formazan by viable cells. Three thousand cells in 200 ml of medium were plated in 96-well plates and grown under normal conditions. Following MTT incubation, 150 ml of 100% dimethylsulphoxide was added to dissolve the crystals. Viable cells were counted every day by reading the absorbance at 490 nm using a 96-plate reader BP800 (Dynex Technologies, Chantilly, VA, USA). Each experiment was performed in triplicate.
Western blot analysis
Protein extraction and immunoblot analyses were performed as described. 21 Cells were washed twice with Hanks balanced salt solution and lysed directly in RIPA buffer (50 mM Tris--HCl pH 7.4, 1% vol/vol Triton X-100, 1 mM EDTA, 1 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF and 1 mM Na3VO4). Lysates were centrifuged at 14 000 r.p.m. for 30 min at 4 1C, and supernatants were collected. Cell lysate (60 mg) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted onto a nitrocellulose membrane and incubated with a primary antibody, including monoclonal antibodies against CIAPIN1 (produced in our laboratory, diluted 1 : 1000); cyclin A, cyclin B, cyclin D1, cyclin E, cyclindependent kinase (cdk) 2, p27 (diluted 1 : 500; BD Biosciences, San Jose, CA); and Rb and phosphorylated Rb (diluted 1 : 500; Cell Signaling Technology, Beverly, MA). b-Actin was used as a loading control in all western blot analyses (diluted 1 : 2000; Sigma Chemical) After repeated washing, the membranes were incubated with horseradish peroxidaseconjugated anti-mouse secondary antibody (diluted 1 : 2000; Santa Cruz Biotechnology, Santa Cruz, CA). The bands were visualized using the enhanced chemiluminescence Q6 system (Amersham Pharmacia Biotech, Buckinghamshire, UK). Each experiment was performed in triplicate. All examined gene expression levels were quantitatively analyzed and expressed as ratios to b-actin.
Clonogenic assay
To measure the proliferative ability of a single cell in vitro, plate clonogenic assays were done. One thousand cells were seeded into a 9-cm dish and cultured in RPMI 1640 for 2 weeks to allow colony formation. Colonies were fixed in 70% ethanol, stained with Giemsa solution and counted.
Tumorigenicity assay BALB/c nude mice were obtained from Shanghai Laboratory Animal Center of the Chinese Academy of Sciences. The mice were maintained under specific pathogen-free conditions in the Experiment Animal Center of the Fourth Military Medical University (Xi'an, Shaanxi Province, People's Republic of China). To prepare tumor cells for inoculation, cells in the exponential growth phase were harvested by brief exposure to a 0.25% trypsin/0.02% EDTA solution (w/v). Mice were injected subcutaneously with 1 Â 10 7 cells in 0.1 ml of serum-free culture medium. The mice were then monitored for tumor volume every week. Animals were killed 6 weeks after injection. Average tumor size was estimated by physical measurement of the excised tumor at the time of killing. Tumor volume was calculated according to the formula: tumor volume ¼ length Â (width) 2 The overall expression level of CIAPIN1 in the pancreatic cancer tissues and the normal pancreatic tissue, it showed significant differences between these two groups pancreatic cancer tissues and the normal pancreatic tissue (Po0.0001). (c) The Kaplan--Meier method was done to calculate the patients' survival durations. Survival durations in the patient groups were calculated with the log-rank test. The survival of 18 patients who had a pancreatic cancer with strong CIAPIN1 expression was significant longer than that of patients with weak CIAPIN1 expression or with negative CIAPIN1 expression (Po0.0001).
Cell cycle analysis
Flow cytometry analysis was performed as described. 22 Cells were seeded overnight on 60-mm-diameter plates in a complete medium, placed in a serum-free medium for 48 h to synchronize the cells and then kept again in the complete medium. At 24 h, cells were recovered. After washing with ice-cold phosphate-buffered saline, cells were suspended in about 0.5 ml of 70% alcohol and kept at 4 1C min. The suspension was filtered through a 50-mm nylon mesh, and the DNA content of stained nuclei was analyzed by a flow cytometer (EPICS XL; Coulter, Miami, FL). Cell cycle was analyzed using Multicycle-DNA Cell Cycle Analyzed Software (Phoenix Flow Systems, San Diego, CA, USA). The proliferous index (PI) was calculated as:
Statistical analysis
We used the two-tailed v2 test to investigate the significance of the difference between the covariates. Pearson's w 2 test was used to calculate patients' sex, depth of invasion, lymph node status, metastasis status and cancer disease stage. Fisher's exact test was done to determine the statistical significance of the relationship of CIAPIN1 expression with histological classification. Age and overall survival of patients with pancreatic cancer was calculated with one-way analysis of variance. The Kaplan--Meier method was done to calculate the patients' survival durations. Survival durations in the patient groups were calculated with the log-rank test. Moreover, we used the Cox proportional hazards model to examine univariate and multivariate hazards ratios for the study variables. All statistical analyses were conducted using SPSS version 11.05 software (SPSS, Chicago, IL). The significance of the in vitro data was determined with Student's t-test (two-tailed), whereas that of the in vivo data was determined with the two-tailed Mann--Whitney U-test. In all of the tests, results were considered statistically significant for Po0.05.
RESULTS
CIAPIN1 expression is lost or absent in primary pancreatic cancer
The expression of CIAPIN1 was assessed by immunohistochemistry in 118 pancreatic cancer samples and 82 adjacent noncancerous tissues. It was found that CIAPIN1 was predominantly located in the cytoplasm and membrane of pancreatic cancerous cells (Figure 1a) . As shown in Figure 1b , CIAPIN1-positive expression in pancreatic cancer specimen was 47.46% (56/118), significantly o75.61% (62/82) in the non-tumor adjacent tissues (Po0.001). Further analysis of the clinic-pathological characteristics from 118 pancreatic cancer specimens, we found that the expression level of CIAPIN1 was inversely correlated with the depth of invasion, tumor metastasis and TNM stage ( Table 1) . The expression of CIAPIN1 in superficial invasion was significantly higher than that in deep invasion (P ¼ 0.0004), the frequency of tumor distant metastasis significantly increased with the decreasing expression level of CIAPIN1 (Po0.0001). The data also indicated that CIAPIN1 were negatively correlated with TNM stage, which means that the less level expression of CIAPIN1, the higher TNM stage (Po0.0001). However, there was no correlation between CIAPIN1 expression and patient age, gender, lymph node status or histology grading. To further confirm these observations, western blot analysis was performed by using five paired human pancreatic cancers and their adjacent normal tissues. The results showed that the tumor tissue specimens had a loss or a drastic decrease in CIAPIN1 expression compared with normal pancreatic tissues (Figure 2a) , which was consistent with the level of CIAPIN1 protein expression determined by immunohistochemical staining. We also compared CIAPIN1 expression in five pancreatic cancer cell lines (PANC-1, ASPC-1, PC-2, PC-3 and BxPC-3) and one immortal pancreatic epithelial cell line (H6C7). As shown in Figure 2b , CIAPIN1 expression was higher in the immortal pancreatic epithelial cell line (H6C7) than in all five pancreatic cancer cell lines.
Loss of CIAPIN1 expression correlates with the poor clinical outcome of pancreatic cancer patients A log-rank test with Kaplan--Meier estimates was adopted to determine whether CIAPIN1 is a significant prognostic factor for the survival of patients with pancreatic cancer. We found that among cancer patients with negative, weak and strong CIAPIN1 expression, their mean disease-specific survival was 10.73 ± 7.65, 18.99±11.56 and 33.14±21.96 months, respectively. Moreover, reduced or negative of CIAPIN1 expression was associated with inferior survival duration by univariate survival analysis (Figure 1c ; Po0.0001). To examine whether CIAPIN1 expression was an independent predictor of patients survival rate or not, a Cox proportional hazards model for multivariate analysis was adopted to research the effect of the covariates including the patients' CIAPIN1 expression level, disease stage, depth of invasion, lymph node status, metastasis, histology grading, age and sex. The results showed that the CIAPIN1 expression was an independent prognostic factor for cancer-specific survival, which was the same as lymph node metastasis.
Overexpression of CIAPIN1 inhibits aggressive phenotype of pancreatic cancer cells in vitro and in vivo As shown in Figure 3a , after transduction, Ad-CIAPIN1 could significantly upregulate the level of CIAPIN1 protein in PANC-1 (Table 2) , whereas only 58.1% of Ad-EGFP-transduced PANC-1 cells and 61.3% of Ad-EGFP-transduced PC-2 cells were arrested at the G0/G1 phase. No significant differences were observed in the fraction of cells in G2-phase. Our results showed a decreased cell population in the S phase after Ad-CIAPIN1 infection in both two cell lines compared with control, as shown in Table 2 . To explore the underlying molecular mechanism of CIAPIN1 affecting the cell cycle progression, we next analyze cell cycle effectors expressions by western blot analysis. Our data showed that upregulation of CIAPIN1 protein was associated with a reducing in cyclin D1, cyclin E, cdk2 and pRb proteins, but with an increase in p27 and Rb proteins (Figure 4 ). In addition, it has no effect on the level of cyclin B and cyclin A proteins. As CIAPIN1 is a cytokine-induced apoptosis inhibitor, we also examined the expression level of apoptosis-related proteins such as bcl-2, bax and bcl-xl. Interestingly, our results showed that enforced expression of CIAPIN1 also led to downregulation of Bcl-2, Bcl-xl, but to upregulation of Bax expression, which indicated that CIAPIN1 might suppress the growth and proliferation of pancreatic cancer cells partly through inducing cell apoptosis.
DISCUSSION
During the carcinogenesis of pancreatic cancer, various genetic and epigenetic alterations accumulated to facilitate cell transformation and to increase aggressive behaviors. Although a number of genes have been identified to be involved in pancreatic carcinogenesis, the tumorigenesis and progression of pancreatic cancer still largely remain unknown. Therefore, it is an urgent need to identify more proteins specifically related to pancreatic carcinogenesis, which may help us to better understand such disease so as to develop new targets for therapy and indicators that is benefit for diagnosis and prognosis. The study showed that CIAPIN1 gene was significantly lowly expressed in pancreatic cancer tissues and in high malignant phenotype of pancreatic cancer cell lines compared with normal pancreatic tissues, which suggested that CIAPIN1 might be involved in the malignant phenotype of pancreatic cancer. Furthermore, our data presented the first evidence that CIAPIN1 was an independent prognostic factor for pancreatic cancer, decrease in CIAPIN1 expression significantly affected the clinical outcome of pancreatic cancer patients and patients with weak or negative CIAPIN1 expression always associated with poor survival duration. All these findings indicate that weak or negative CIAPIN1 expression is significantly related to aggressive phenotype of pancreatic cancer; CIAPIN1 might be a new prognostic marker for pancreatic cancer and a promising molecular target for its gene therapy. Expression level of CIAPIN1 in pancreatic cancer tissues and normal pancreatic tissues is significantly different. It suggested that CIAPIN1 could have important roles in pancreatic carcinogenesis and might have an inhibitory effect on the proliferation of pancreatic cancer cells. To probe whether the ectopic expression of CIAPIN1 could have an effect on the proliferation of pancreatic cancer cells? Ad-EGFP and Ad-CIAPIN1 were transfected into BxPC-3 and PC-3 cells, respectively. The result showed that CIAPIN1 significantly inhibited pancreatic cancer cell proliferation and growth in vitro and tumorigenicity in animal models.
Interestingly, our present study found that enforced expression of CIAPIN1 delayed the progress of cell cycle by regulation of the G1/S phase cell cycle. It is well known that cell cycle initiation and progression are regulated by several classic cell cycle regulator cyclins, cyclin-dependent kinase (cdk) and cdk inhibitor molecules., Beyond mid-G1, near the end of the G1/S restriction point, the expression of cyclin E with cdk2 has been shown to promote the phosphorylation of Rb and in the end promote S phase entry. 23, 24 Cyclin A/cdk2 complex has been shown to preserve the phosphorylation of Rb during the S-phase of the cell cycle beyond the G1/S restriction point. 25, 26 The disorder of CDKIs is a common property in tumor cells and mainly leads to the disruption of cell cycle regulation; and p27Kip1 (p27) is a CDKI that has its inhibitory activity on many steps of the cell cycle. 27 Our results clearly showed that upregulation of CIAPIN1 was associated with the reduction of cyclin E, cyclinD1, cdk2 and phosphorylated Rb proteins expression, and simultaneously increased the expression of p27 and Rb proteins. These data suggested that CIAPIN1 might stimulate pancreatic cancer proliferation by selectively regulating specific cell cycle effectors and thus, facilitating cell cycle transition from G1 to S phase. As CIAPIN1 is a cytokine-induced apoptosis inhibitor, we also examined the expression level of apoptosis-related proteins such as bcl-2, bax and bcl-xl. The results showed that enforced expression of CIAPIN1 also led to downregulation of Bcl-2, Bcl-xl, but upregulation of Bax expression, which indicated that CIAPIN1 might suppress the growth and proliferation of pancreatic cancer cells partly through inducing cell apoptosis. All of these results strongly suggested that enforced expression of CIAPIN1 might decrease the malignant phenotype of pancreatic cancer cells through different molecular pathway and there is still a long way to go to further confirm the exact function of CIAPIN1 in pancreatic cancer cells and the precise molecular mechanism.
The function of CIAPIN1 found in pancreatic cancer cells is consistency with what found in renal cancer cells and gastric cancer cells, and it seems totally different compared with hepatocellular carcinoma cells, colon cancer cells, breast cancer cells, thyroid cancer cells and diffuse large B-cell lymphoma cells. 10,11,28--32 It seems that CIAPIN1 might have contrary function among these different cancer cell lines. These opposite results might be explained by CIAPIN1 having different function in different cancer cell lines through different signal pathway. The discrepancy in different cancers cells might also be possible due to the differential expression of CIAPIN1 splice variants, and further experiments are needed to explore the exact function of CIAPIN1 in pancreatic cancer.
In summary, experimental evidences confirmed that loss or low level of CIAPIN1 protein was a frequent event in human pancreatic cancer and upregulation of CIAPIN1 could suppress the proliferation of pancreatic cancer cells at least partly through delaying cell cycle progression and inducing cell apoptosis. Our data also suggested that CIAPIN1 may not only a useful molecular marker for predicting the survival in pancreatic cancer but also be an effective therapeutic target for pancreatic cancer. Further works are required to better understand the exact molecular mechanism for aberrant CIAPIN1 signaling pathway, which may help us to design an effective therapeutic modality to control pancreatic cancer.
